This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of BBP-398, an SHP2 inhibitor with indications for NSCLC and advanced solid tumor
Ticker(s): BBIOWho's the expert?
Institution: Self-employed
- Medical oncologist/hematologist who specializes in adult cancer medicine, hematology, coagulation, familial cancer, and venous thrombosis.
- In practice for nearly 30 years and has been published extensively over the years in medical journals
- Served as a clinical investigator in multiple hematology/oncology areas, such as hematology coagulation, pain medication and pharmaceuticals in the past.
Interview GoalIn addition, this call will also be focused on reviewing the Phase 1 clinical trial of BBP-398 in combination with nivolumab in patients with NSCLC (NCT05375084)
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
